Skip to content
Ecat.nl
Ecat.nl
Home
Docs
Haemostatic Cascade
Activation of Protein C by Thrombin
Activation of Protein C by Thrombin
Related items
Cases : 6
Haemophilia B and treatment, case study
Haemophilia A and treatment, case study
A severe haemophilia A patient treated with emicizumab, case study
Acquired haemophilia A
Acquired Hemophilia A, case study
Factor V Inhibitor
Analytical Information : 6
Literature Review: Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays
Literature Review: The responsiveness of different APTT reagents to mild factor VIII, IX and XI deficiencies
Results of a workshop on the inter-laboratory variability of analysis of type 1 factor VIII Inhibitors
The do’s and don’ts of laboratory detection of haemostasis-inhibitors: lessons from a workshop
Analytical performance specifications for hemostasis parameters
The effect of Rivaroxaban on haemostasis assays; results from ECAT surveys
Guidelines : 1
Recommendations for laboratory measurement of factor VIII and FIX type I inhibitors, ICSH recommendations
Test Information : 17
The genetic background of haemophilia
The future of haemophilia treatment: beyond the suppletion of factor VIII and IX
Role of gene therapy in the future treatment of haemophilia patients
Potency labelling of extended half-life FVIII and FIX products
Personalising therapy in haemophilia Pharmacokinetic-guided dosing of factor VIII and factor IX concentrates
Patient-tailored therapy in haemophilia A: Towards pharmacokinetically guided dosing of factor VIII replacement therapy
Optimizing prophylactic treatment in haemophilia: when to use longer-acting products
New developments in the treatment of haemophilia
New developments in the treatment of haemophilia: implications for laboratory testing
Measurement of Factor VIII inhibitors: Detection, Improvement and Perspectives
Measurement of factor VIII for the diagnosis of haemophilia A
Laboratory monitoring of new hemostatic agents (Long-acting factor concentrates)
Laboratory measurement of extended half-life FIX concentrates
Inhibitors in mild or moderate hemophilia A
The detection of Factor VIII Inhibitors with the Nijmegen assay
Clinical features of inhibitors in haemophilia A
Antibodies to blood coagulation factors; immunological background
Quality Issues : 3
Quality Assurance of replacement therapy and future perspectives
External quality assessment for Factor VIII and Factor IX
The between-laboratoy variation of Factor VIII inhibitor testing
Laboratory Tests : 10
Protein C (ProC) Global Assay
Activated Protein C resistance (APC-R)
Protein C (Clotting-based, Immunological and Chromogenic)
Factor VIII Binding (VWF:FVIIIB)
Factor VIII inhibitor
Factor IX (Chromogenic)
Factor VIII (Clotting-based and Chromogenic)
Factor X Assay (RVV)
Factor Assays APTT-Based (1-Stage)
Factor Assays PT-Based (1-Stage)
Haemostatic Cascade : 8
TF Pathway (Extrinsic) with Common Pathway (PT)
Nucleotide sequences of RNA Codons Encoding for Amino Acids
Intrinsic Pathway APTT
Fibrinolytic Pathway
Coagulation Pathways (All Components)
Amino Acid structure of Natural Hirudin
Activation of TAFI by Thrombin
Activation of Platelets by Thrombin
Factor VIII Inhibitor : 2
Normal pooled plasma
Factor VIII deficient plasma
Clotting factor (II, V, VII and X) : 3
Calibrators II V VII X
Deficient plasma II V VII X
Activator II V VII X
Clotting factor (VIII, IX, XI and XII) : 7
FIX antigen
FVIII antigen
Calibrators VIII IX XI XII
Factor IX chromogenic methods
Factor VIII chromogenic methods
Deficient plasma FVIII IX XI XII
Activator VIII IX XI XII
Thrombophilia : 3
Protein C pathway test
Protein C antigen
Protein C activity
Questions or suggestions?
Clotpedia Support Form
Submit
Success
